Review decision – December 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA370; Bortezomib for previously untreated mantle cell lymphoma.
No new evidence was identified that is likely to change the existing recommendations in TA370.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA370 will move to the ‘static list’ of technology appraisals.
This page was last updated: